Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
On Monday, Revelation Biosciences Inc (NASDAQ:REVB) announced safety and biomarker data for its Phase 1 study (RVL-HV02).
周一，Revelation Biosciences Inc（纳斯达克：REVB）宣布其一期研究（RVL-HV02）的安全性和生物标志物数据。
The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.
评估升级剂量Gemini的安全性和耐受性的主要终点已得到满足，并确定了健康志愿者的最大耐受剂量。
Additionally, statistically significant dose-dependent upregulation of key biomarkers demonstrating the immunostimulatory preconditioning effect of Gemini was observed.
此外，观察到关键生物标志物的剂量依赖性上调，表明Gemini具有免疫前调效应，达到统计显著性。
The study enrolled 40 healthy individuals 18 to 55 years of age.
该研究招募了40名年龄在18至55岁的健康个体。
Administration of Gemini induced significant, dose-dependent changes in key circulatory biomarkers of activity that reflect the expected pharmacology of Gemini-specific toll-like receptor 4 (TLR4) stimulation.
Gemini的静脉注射引起了循环生物标志物活动的显著、剂量依赖性变化，反映了特异性toll样受体4（TLR4）激活的药理学预期。
Intravenous Gemini induced significant increases in interleukin-1RA (IL-1RA) (p<0.001 at mid and high dose), neutrophil gelatinase lipocalin (NGAL) (p<0.01 at mid and high dose), c-reactive protein (CRP) (p<0.001 at mid and high dose), and IL-6 (p<0.01 at high dose).
静脉注射Gemini显著增加了白细胞介素1RA（IL-1RA）（中、高剂量p
Significant, dose-dependent mobilization of innate immune cell populations was observed, specifically neutrophils (p<0.001 at mid-dose and high dose) and monocytes (p<0.001 at mid and high dose).
观察到显著、剂量依赖性的先天免疫细胞群体动员，特别是中性粒细胞（中剂量和高剂量p
Gemini administration did not induce significant increases in serum TNF-α (p=0.51 at the highest dose) and IL-1β (p=0.89 at the highest dose).
Gemini注射未引起血清TNF-α（最高剂量p = 0.51）和IL-1β（最高剂量p = 0.89）的显著增加。
Gemini administration was generally well-tolerated.
Gemini注射通常耐受。
"With this new data, we are excited and committed to moving rapidly into a Phase 1b study in patients in late 2024," said James Rolke, Chief Executive Officer of Revelation.
“有了这个新数据，我们很兴奋并致力于2024年底快速进入患者的1b期研究，” Revelation首席执行官James Rolke表示。
Gemini is initially being developed as a single-dose preconditioning therapy for two target indications:
Gemini最初作为两个目标适应症的单剂量预处理疗法开发：
- As a pretreatment to prevent or reduce the severity of acute kidney injury due to cardiac surgery (GEMINI-AKI program).
- As a pretreatment to reduce the incidence, duration, and severity of post-surgical infection (GEMINI-PSI program).
- 作为预处理以防止或减轻因心脏手术而导致的急性肾损伤（GEMINI-AKI计划）。
- 作为预处理以减少手术后感染的发生率、持续时间和严重程度（GEMINI-PSI计划）。
Price Action: REVB shares are up 31.30% at $2.77 at the last check on Monday.
价格行动：REVB股票在周一最后交易时上涨31.30％，至2.77美元。